CSL Alentis Partnership: $1.6B Lixudebart Deal Explained
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.